SQZ Biotechnologies Total Liabilities 2020-2022 | SQZ

SQZ Biotechnologies total liabilities from 2020 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
SQZ Biotechnologies Annual Total Liabilities
(Millions of US $)
2021 $102
2020 $104
2019 $94
SQZ Biotechnologies Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $96
2021-12-31 $102
2021-09-30 $111
2021-06-30 $86
2021-03-31 $94
2020-12-31 $104
2020-09-30 $107
2020-06-30 $0
2020-03-31 $0
2019-12-31
2019-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00